↓ Skip to main content

Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy

Overview of attention for article published in JACC: Heart Failure, May 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 527)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
84 news outlets

Readers on

mendeley
4 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy
Published in
JACC: Heart Failure, May 2017
DOI 10.1016/j.jchf.2017.02.017
Pubmed ID
Authors

Stephan Schürer, Karin Klingel, Marcus Sandri, Nicolas Majunke, Christian Besler, Reinhard Kandolf, Philipp Lurz, Michael Luck, Pia Hertel, Gerhard Schuler, Axel Linke, Norman Mangner, Schürer, Stephan, Klingel, Karin, Sandri, Marcus, Majunke, Nicolas, Besler, Christian, Kandolf, Reinhard, Lurz, Philipp, Luck, Michael, Hertel, Pia, Schuler, Gerhard, Linke, Axel, Mangner, Norman

Abstract

This study aimed to assess characteristics including endomyocardial biopsy and outcome of patients with methamphetamine (MA)-associated cardiomyopathy in a series of patients treated in Germany. MA abuse is an increasing problem worldwide. The cases of 30 consecutive MA-abusing patients with a left ventricular (LV) ejection fraction of <40% and endomyocardial biopsy performed at initial diagnosis were analyzed. Baseline characteristics were collected retrospectively, whereas follow-up was prospective. The primary endpoint was a composite of death, nonfatal stroke, and rehospitalization for heart failure. Patients were 30.3 ± 1.9 years of age, predominantly male (93.3%), and highly symptomatic; 83.3% had New York Heart Association functional class III or IV dyspnea. Echocardiography revealed marked LV dilatation (mean LV end-diastolic diameter 67.1 ± 7.4 mm) and impaired LV ejection fraction (mean 19 ± 6%). One-third of the patients had intraventricular thrombi. Endomyocardial biopsy revealed markers of inflammation and fibrosis; the fibrosis correlated with the duration of MA abuse. At follow-up, discontinuation of MA abuse together with medical therapy partially improved cardiac function (LV ejection fraction, 19 ± 6 vs. 43 ± 13; p < 0.001) and symptoms (p = 0.056), whereas patients with continued abuse did not show any improvement. The improvement in cardiac function was independently associated with the extent of fibrosis. The primary endpoint occurred more often in patients with continued MA abuse (57.1% vs. 13.0%; p = 0.037). MA-associated cardiomyopathy is characterized by severe heart failure and depressed cardiac function. The extent of myocardial fibrosis seems to predict the recoverability of LV function. Cessation of MA abuse is associated with improvement in cardiac function and symptoms, whereas continued MA abuse leads to ongoing heart failure and worse outcome.

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 50%
Student > Ph. D. Student 1 25%
Researcher 1 25%
Readers by discipline Count As %
Nursing and Health Professions 1 25%
Agricultural and Biological Sciences 1 25%
Psychology 1 25%
Medicine and Dentistry 1 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 648. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 June 2017.
All research outputs
#4,658
of 8,307,635 outputs
Outputs from JACC: Heart Failure
#1
of 527 outputs
Outputs of similar age
#370
of 241,029 outputs
Outputs of similar age from JACC: Heart Failure
#1
of 31 outputs
Altmetric has tracked 8,307,635 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 527 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,029 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.